379 A phase 2, randomized, placebo-controlled, double-blind, ascending dose study to evaluate efficacy, safety, tolerability, pharmacokinetics, pharmacodynamics & pharmacogenetics of CC-220 in subjects with SLE
V. Werth(University of Pennsylvania), Seohee Choi, Nikolay Delev(Bristol-Myers Squibb (Sweden)), David Hough(Janssen (Belgium)), Shimon Korish(Bristol-Myers Squibb (United States)), Richard Furie(Hofstra University), Peter Schäfer(Bristol-Myers Squibb (United States)), A Azarian, Michael Weiswasser(Bristol-Myers Squibb (United States))
Cited by 0
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
|American Journal of Psychiatry|2019|888
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840